비결핵성 항산균(NTM) 시장 : 약물 유형별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Nontuberculous Mycobacteria Market size was valued at USD 9,320.34 Million in 2023, expanding at a CAGR of 3.14% from 2024 to 2032.

Nontuberculous mycobacteria are a collection of bacteria that naturally exist in soil, water, and dust all over the world. Non-tuberculous mycobacteria (NTM) refers to a group of over 190 species of Mycobacterium, excluding Mycobacterium tuberculosis and Mycobacterium leprae. These microorganisms are present everywhere in the environment, especially in soil and water sources, and are increasingly being recognized as a cause of human diseases. Non-tuberculous mycobacteria can infect not only individuals with weakened immune systems but also those who are otherwise healthy. The diagnosis and management of NTM infections pose numerous challenges.

Nontuberculous Mycobacteria Market- Market Dynamics

Increasing occurrence of nontuberculous mycobacterial lung illness, particularly amongst the older population worldwide, is projected to propel market's growth.

The aging global population is experiencing a significant rise in the number of elderly individuals. Due to the fact that age is a risk factor for NTM lung disease, the increasing elderly demographic is anticipated to contribute to the growing incidence of the illness, thereby creating a higher demand for diagnostic and therapeutic solutions. The improved awareness among healthcare providers and patients regarding NTM lung disease, along with better access to healthcare services, has resulted in increased rates of diagnosis and treatment. According to the National Health Service, in 2021, the mortality rate from respiratory conditions (as either the primary or associated cause) was more prevalent among older individuals (73% of respiratory deaths occurred in individuals aged 75 and above, compared to 67% for total deaths). Additionally, advancements in diagnostic techniques, such as high-throughput sequencing and enhanced culture methods, could present growth opportunities for the market. Nevertheless, the high cost of treatment may impede the market's growth.

Nontuberculous Mycobacteria Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.14% over the forecast period (2024-2032)

Based on Drug Class segmentation, Oral Antibiotics was predicted to show maximum market share in the year 2023

On the basis of region, North America was the leading revenue generator in 2023

Nontuberculous Mycobacteria Market- Segmentation Analysis:

The Global Nontuberculous Mycobacteria Market is segmented on the basis of Drug Class, Distribution Channel, and Region.

The market is segmented into four categories according to Drug Class: Oral Antibiotics, IV Antibiotics, Anti-Nausea, and Nebulized Antibiotics. The Oral Antibiotics category holds the largest share in the market. Various factors such as the prevalence of NTM-related diseases, the effectiveness of existing antibiotics, treatment protocols, and regulatory authorizations impact the market for oral antibiotics utilized in treating nontuberculous mycobacteria (NTM) infections.

The market is categorized into three segments according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Pharmaceutical companies that manufacture antibiotics and other medications for NTM infections distribute their products through conventional pharmaceutical distribution channels.

Nontuberculous Mycobacteria Market- Geographical Insights

This market is geographically spread across various regions, namely North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increased research efforts in developing new medications and the rising healthcare expenses. There is a notable surge in research and development endeavors focused on discovering new antibiotics and treatment regimens for NTM infections. In the United States, health spending witnessed a 2.7% increase in 2021, reaching USD4.3 trillion or USD12, 914 per capita. This growth rate is significantly lower than that of 2020 (10.3%), stated by the American Medical Association. Europe holds the second-largest region for this market, primarily due to the rising rates of infectious illnesses.

Nontuberculous Mycobacteria Market- Competitive Landscape:

Various pharmaceutical companies specializing in the development of antibiotics and other therapeutics for NTM infections are the main competitors in this market. They compete based on factors like product effectiveness, safety, and pricing, as well as strategies to secure market access. Competition may also involve creating new antibiotics with better activity against NTM species or formulations that improve patient adherence and outcomes. The rivalry in the NTM market extends to the clinical development pipeline, where companies aim to introduce new treatments or expand existing product indications. Overall, competition in the NTM market is shaped by product differentiation, clinical development efforts, regulatory factors, market access plans, research and innovation, and collaborations.

Recent Developments:

On June 16, 2020, Novartis ILARIS (canakinumab) was approved by the US Food and Drug Administration (FDA) for a new indication to treat Adult-Onset Still's Disease (AOSD). The FDA granted approval for active Still's disease, which includes both systemic juvenile idiopathic arthritis (SJIA) and AOSD, in patients aged 2 years and older.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Insmed, RedHill Biopharma Ltd

Novartis AG

Paratek Pharmaceuticals Inc

Janssen

RevImmune

Nobelpharma Co Ltd

Others

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

• Oral Antibiotics
• IV Antibiotics
• Anti Nausea
• Nebulized Antibiotics

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1.Nontuberculous Mycobacteria Market Overview

• 1.1.Study Scope
• 1.2.Market Estimation Years

2.Executive Summary

• 2.1.Market Snippet
  • 2.1.1.Nontuberculous Mycobacteria Market Snippet by Drug Class
  • 2.1.2.Nontuberculous Mycobacteria Market Snippet by Distribution Channel
  • 2.1.3.Nontuberculous Mycobacteria Market Snippet by Country
  • 2.1.4.Nontuberculous Mycobacteria Market Snippet by Region
• 2.2.Competitive Insights

3.Nontuberculous Mycobacteria Key Market Trends

• 3.1.Nontuberculous Mycobacteria Market Drivers
  • 3.1.1.Impact Analysis of Market Drivers
• 3.2.Nontuberculous Mycobacteria Market Restraints
  • 3.2.1.Impact Analysis of Market Restraints
• 3.3.Nontuberculous Mycobacteria Market Opportunities
• 3.4.Nontuberculous Mycobacteria Market Future Trends

4.Nontuberculous Mycobacteria Industry Study

• 4.1.PEST Analysis
• 4.2.Porter's Five Forces Analysis
• 4.3.Growth Prospect Mapping
• 4.4.Regulatory Framework Analysis

5.Nontuberculous Mycobacteria Market: COVID-19 Impact Analysis

• 5.1.Pre-COVID-19 Impact Analysis
• 5.2.Post-COVID-19 Impact Analysis
  • 5.2.1.Top Performing Segments
  • 5.2.2.Marginal Growth Segments
  • 5.2.3.Top Looser Segments
  • 5.2.4.Marginal Loss Segments

6.Nontuberculous Mycobacteria Market Landscape

• 6.1.Nontuberculous Mycobacteria Market Share Analysis, 2023
• 6.2.Breakdown Data, by Key Manufacturer
  • 6.2.1.Established Players' Analysis
  • 6.2.2.Emerging Players' Analysis

7.Nontuberculous Mycobacteria Market - By Drug Class

• 7.1.Overview
  • 7.1.1.Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
  • 7.1.2.Oral Antibiotics
  • 7.1.3.IV Antibiotics
  • 7.1.4.Anti-Nausea
  • 7.1.5.Nebulized Antibiotics

8.Nontuberculous Mycobacteria Market - By Distribution Channel

• 8.1.Overview
  • 8.1.1.Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
  • 8.1.2.Hospital pharmacies
  • 8.1.3.Retail pharmacies
  • 8.1.4.Online pharmacies

9.Nontuberculous Mycobacteria Market- By Geography

• 9.1.Introduction
  • 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 9.2.North America
  • 9.2.1.Overview
  • 9.2.2.Nontuberculous Mycobacteria Key Manufacturers in North America
  • 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.2.4.North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 9.2.5.North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.2.6.U.S.
    • 9.2.6.1.Overview
    • 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.6.3.U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.2.6.4.U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.2.7.Canada
    • 9.2.7.1.Overview
    • 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.7.3.Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.2.7.4.Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 9.3.Europe
  • 9.3.1.Overview
  • 9.3.2.Nontuberculous Mycobacteria Key Manufacturers in Europe
  • 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.3.4.Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 9.3.5.Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.6.Germany
    • 9.3.6.1.Overview
    • 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.6.3.Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.6.4.Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.7.Italy
    • 9.3.7.1.Overview
    • 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.7.3.Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.7.4.Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.8.United Kingdom
    • 9.3.8.1.Overview
    • 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.8.3.United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.8.4.United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.9.France
    • 9.3.9.1.Overview
    • 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.9.3.France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.9.4.France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.10.Russia
    • 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.10.2.Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.10.3.Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.11.Netherlands
    • 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.11.2.Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.11.3.Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.12.Sweden
    • 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.12.2.Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.12.3.Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.13.Poland
    • 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.13.2.Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.13.3.Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.14.Rest of Europe
    • 9.3.14.1.Overview
    • 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.14.3.Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.14.4.Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 9.4.Asia Pacific (APAC)
  • 9.4.1.Overview
  • 9.4.2.Nontuberculous Mycobacteria Key Manufacturers in Asia Pacific
  • 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.4.4.Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 9.4.5.Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.6.India
    • 9.4.6.1.Overview
    • 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.6.3.India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.6.4.India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.7.China
    • 9.4.7.1.Overview
    • 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.7.3.China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.7.4.China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.8.Japan
    • 9.4.8.1.Overview
    • 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.8.3.Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.8.4.Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.9.South Korea
    • 9.4.9.1.Overview
    • 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.9.3.South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.9.4.South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.10.Australia
    • 9.4.10.1.Overview
    • 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.10.3.Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.10.4.Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.11.Thailand
    • 9.4.11.1.Overview
    • 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.11.3.Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.11.4.Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.12.Indonesia
    • 9.4.12.1.Overview
    • 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.12.3.Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.12.4.Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.13.Philippines
    • 9.4.13.1.Overview
    • 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.13.3.Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.13.4.Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.14.Rest of APAC
    • 9.4.14.1.Overview
    • 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.14.3.Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.14.4.Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 9.5.Latin America
  • 9.5.1.Overview
  • 9.5.2.Nontuberculous Mycobacteria Key Manufacturers in Latin America
  • 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.5.4.Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 9.5.5.Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.6.Brazil
    • 9.5.6.1.Overview
    • 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.6.3.Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.6.4.Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.7.Mexico
    • 9.5.7.1.Overview
    • 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.7.3.Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.7.4.Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.8.Argentina
    • 9.5.8.1.Overview
    • 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.8.3.Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.8.4.Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.9.Colombia
    • 9.5.9.1.Overview
    • 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.9.3.Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.9.4.Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.10.Rest of LATAM
    • 9.5.10.1.Overview
    • 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.10.3.Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.10.4.Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 9.6.Middle East and Africa
  • 9.6.1.Overview
  • 9.6.2.Nontuberculous Mycobacteria Key Manufacturers in Middle East and Africa
  • 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.6.4.Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 9.6.5.Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.6.Saudi Arabia
    • 9.6.6.1.Overview
    • 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.6.3.Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.6.4.Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.7.United Arab Emirates
    • 9.6.7.1.Overview
    • 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.7.3.United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.7.4.United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.8.Israel
    • 9.6.8.1.Overview
    • 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.8.3.Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.8.4.Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.9.Turkey
    • 9.6.9.1.Overview
    • 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.9.3.Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.9.4.Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.10.Algeria
    • 9.6.10.1.Overview
    • 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.10.3.Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.10.4.Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.11.Egypt
    • 9.6.11.1.Overview
    • 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.11.3.Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.11.4.Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.12.Rest of MEA
    • 9.6.12.1.Overview
    • 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.12.3.Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.12.4.Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Nontuberculous Mycobacteria Industry

• 10.1.Competitive Dashboard
• 10.2.Company Profiles
  • 10.2.1.Insmed, RedHill Biopharma Ltd
  • 10.2.2.Novartis AG
  • 10.2.3.Paratek Pharmaceuticals Inc
  • 10.2.4.Janssen
  • 10.2.5.RevImmune
  • 10.2.6.Nobelpharma Co Ltd
  • 10.2.7.Others

11.360 Degree Analyst View

12.Appendix

• 12.1.Research Methodology
• 12.2.References
• 12.3.Abbreviations
• 12.4.Disclaimer
• 12.5.Contact Us